Calamos Advisors
AZN icon

Calamos Advisors’s AstraZeneca AZN Stock Holding History

Calamos Advisors’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-33,768
Closed -$6.66M – 1001
2026
Q1 		$6.66M Buy
33,768
+27,329
+424% +$5.27M 0.02% 497
2025
Q4 		$1.18M Buy
6,439
+345
+6% +$60.5K ﹤0.01% 670
2025
Q3 		$935K Sell
6,094
-2
-0% -$303 ﹤0.01% 713
2025
Q2 		$852K Buy
6,096
+3
+0% +$420 ﹤0.01% 709
2025
Q1 		$896K Buy
6,093
+23
+0.4% +$3.33K ﹤0.01% 661
2024
Q4 		$795K Buy
6,070
+35
+0.6% +$4.9K ﹤0.01% 692
2024
Q3 		$940K Hold
6,035
– – ﹤0.01% 673
2024
Q2 		$941K Sell
6,035
-38
-0.6% -$5.72K ﹤0.01% 653
2024
Q1 		$823K Buy
+6,073
New +$804K ﹤0.01% 662
2021
Q4 		– Sell
-148,454
Closed -$17.8M – 1122
2021
Q3 		$17.8M Buy
+148,454
New +$17.3M 0.08% 277
2019
Q3 		– Sell
-37,213
Closed -$3.07M – 747
2019
Q2 		$3.07M Sell
37,213
-12,287
-25% -$963K 0.02% 584
2019
Q1 		$4M Hold
49,500
– – 0.03% 493
2018
Q4 		$3.76M Buy
49,500
+4,850
+11% +$379K 0.02% 494
2018
Q3 		$3.53M Buy
+44,650
New +$3.38M 0.02% 520

Other funds holding AZN

EPGL
Evelyn Partners Group Ltd London $46.9B AUM
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
RG
Rathbones Group Liverpool, United Kingdom $27.1B AUM 20.2% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
SAM
SEB Asset Management Stockholm $26.6B AUM
CDDEC
Caisse Des Depots Et Consignations Paris, France $5.91B AUM 35.65% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
MGP
M&G plc London, United Kingdom $20.1B AUM 16.62% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

Calamos Advisors's AZN Position: Q2 2026 in Review

Calamos Advisors sold out of AstraZeneca (AZN) in Q2 2026, closing a stake of 33,768 shares — an estimated $6.66M sold.

Calamos Advisors first reported a position in AZN in Q3 2018 and held it in 14 quarters. The position peaked at $17.8M in Q3 2021. 906 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

  • Calamos Advisors reported no remaining AstraZeneca position as of Q2 2026 after selling out during the quarter.
  • Calamos Advisors sold 33,768 AstraZeneca shares in Q2 2026, an estimated $6.66M.
  • Calamos Advisors first reported a position in AstraZeneca in Q3 2018 and held it in 14 quarters.
  • Calamos Advisors's AstraZeneca position peaked at $17.8M in Q3 2021.
  • 906 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Calamos Advisors's 13F filing for Q2 2026, filed 31 Jul 2026.